Kalantar-Zadeh, Kamyar
Ficociello, Linda H.
Parameswaran, Vidhya
Athienites, Nicolaos V.
Mullon, Claudy
Kossmann, Robert J.
Coyne, Daniel W. http://orcid.org/0000-0001-9786-5235
Funding for this research was provided by:
Fresenius Medical Care Renal Therapies Group
Article History
Received: 23 July 2019
Accepted: 3 October 2019
First Online: 29 October 2019
Ethics approval and consent to participate
: This manuscript reports data from a retrospective analysis. The need for informed consent was waived by the New England Institutional Review Board (Needham, Massachusetts) because of the anonymous and purely observational nature of the study.
: Not applicable.
: LHF, VP, CM, and RJK are employees of Fresenius Medical Care Renal Therapies Group. LHF, CM, and RJK own stock in Fresenius Medical Care North America. RJK is on the Board of Directors of Advanced Renal Technologies. DWC is a consultant and speaker for Fresenius Medical Care. KK-Z has received honoraria and/or support from Abbott, AbbVie, Alexion, American Society of Nephrology, Amgen, AstraZeneca, AVEO, Chugai, DaVita, Fresenius, Fresenius Kabi, Genentech, Haymarket Media, Hofstra Medical School, Hospira, International Federation of Kidney Foundations, International Society for Hemodialysis, International Society of Renal Nutrition and Metabolism, Japanese Society for Dialysis Therapy, Keryx, National Institutes of Health, National Kidney Foundation, Novartis, OPKO, Pfizer, Relypsa, Resverlogix, Sandoz, Sanofi, Shire, UpToDate, Vifor, and ZS Pharma. NVA received honoraria for advisory boards from Fresenius Medical Care and Mallinckrodt and is a speaker for Mallinckrodt.